Ophthotech Corporation has announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium) for treatment of advanced dry macular degeneration (MD). Zimura® is an inhibitor of complement factor C5, a central component of the complement cascade believed to be involved in the development of AMD. The Company has also recently [Read More]
News
Let’s Be Clear About Blue Light
Editorial by Dan Roberts The media is becoming saturated with warnings about the so-called “blue light hazard”. Let’s pull it back a bit by being more specific about who should be most concerned. In 2006, I published a paper titled Artificial Lighting and the Blue Light Hazard. The purpose of the paper was to warn of [Read More]
New Study Underway for Treatment of Dry Macular Degeneration
Subjects are being sought for trials to test the new Nova Oculus™ device as the only scientifically supported treatment for dry macular degeneration. Presently, no scientifically proven treatment option is available for those with dry macular degeneration (dMD). Ongoing research, however, is showing that a new device using biocurrent technology (very low micro-current electrical stimulation) [Read More]
Glaucoma Awareness Can Help Save Your Vision
Important Information from the National Eye Institute Glaucoma is a major cause of vision loss in the U.S. While it currently affects about 3 million Americans, estimates show 6.3 million could have glaucoma by 2050. With Glaucoma Awareness Month in January, it’s a good time to think about scheduling a comprehensive dilated eye exam, especially [Read More]
Triple Therapy with Zeaxanthin Lessens Burden of Treatment for Wet AMD
As far back as 2007, triple therapy for wet (neovascular) age-related macular degeneration (AMD) was shown to be superior to mono therapy (intraocular injection of a single anti-VEGF drug).* And now, a study described in a recent online publication of the peer-reviewed monthly, International Journal of Retina and Vitreous, found that triple therapy supplemented with [Read More]